{
    "root": "187b02db-6d50-4cc8-9800-8759ee7220a1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ibrance",
    "value": "20250314",
    "ingredients": [
        {
            "name": "PALBOCICLIB",
            "code": "G9ZF61LE7G"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O"
        }
    ],
    "indications": "ibrance indicated treatment adult patients hormone receptor ( hr ) -positive , human epidermal growth factor receptor 2 ( her2 ) -negative advanced metastatic breast cancer combination : \u2022an aromatase inhibitor initial endocrine-based therapy ; \u2022fulvestrant patients disease progression following endocrine therapy .",
    "contraindications": "ibrance capsules taken orally food combination aromatase inhibitor fulvestrant . ( 2 ) \u2022 recommended starting dose : 125 mg daily taken food 21 days followed 7 days treatment . ( 2.1 ) \u2022 dosing interruption and/or dose reductions recommended based individual safety tolerability . ( 2.2 )",
    "warningsAndPrecautions": "ibrance supplied following strengths package configurations : ibrance capsules package configuration capsule strength ( mg ) ndc capsule description bottles 21 capsules 125 ndc 0069-0189-21 opaque , hard gelatin capsules , size 0 , caramel cap body , printed white ink `` pfizer `` cap , `` pbc 125 `` body bottles 21 capsules 100 ndc 0069-0188-21 opaque , hard gelatin capsules , size 1 , caramel cap light orange body , printed white ink `` pfizer `` cap , `` pbc 100 `` body bottles 21 capsules 75 ndc 0069-0187-21 opaque , hard gelatin capsules , size 2 , light orange cap body , printed white ink `` pfizer `` cap , `` pbc 75 `` body",
    "adverseReactions": "none .",
    "indications_original": "IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:\n                  \n                     \n                        \u2022an aromatase inhibitor as initial endocrine-based therapy; or\n                     \n                        \u2022fulvestrant in patients with disease progression following endocrine therapy.",
    "contraindications_original": "IBRANCE capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant. ( 2 ) \u2022 Recommended starting dose: 125 mg once daily taken with food for 21 days followed by 7 days off treatment. ( 2.1 ) \u2022 Dosing interruption and/or dose reductions are recommended based on individual safety and tolerability. ( 2.2 )",
    "warningsAndPrecautions_original": "IBRANCE is supplied in the following strengths and package configurations:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              IBRANCE Capsules\n                           \n                        \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Capsule Strength (mg)\n                           \n                           \n                              NDC\n                           \n                           \n                              Capsule Description\n                           \n                        \n                     \n                     \n                        \n                           \n                              Bottles of 21 capsules\n                           \n                           \n                              125\n                           \n                           \n                              NDC 0069-0189-21\n                           \n                           \n                              opaque, hard gelatin capsules, size 0, with caramel cap and body, printed with white ink \"Pfizer\" on the cap, \"PBC 125\" on the body\n                           \n                        \n                        \n                           \n                              Bottles of 21 capsules\n                           \n                           \n                              100\n                           \n                           \n                              NDC 0069-0188-21\n                           \n                           \n                              opaque, hard gelatin capsules, size 1, with caramel cap and light orange body, printed with white ink \"Pfizer\" on the cap, \"PBC 100\" on the body\n                           \n                        \n                        \n                           \n                              Bottles of 21 capsules\n                           \n                           \n                              75\n                           \n                           \n                              NDC 0069-0187-21\n                           \n                           \n                              opaque, hard gelatin capsules, size 2, with light orange cap and body, printed with white ink \"Pfizer\" on the cap, \"PBC 75\" on the body",
    "adverseReactions_original": "None."
}